News | Telecardiology | May 15, 2020

Telemedicine-based Network Offers Remote Guidance to 100 Million STEMI Patients

Study investigators have created a template for reducing disparities in STEMI management between developed and developing countries

The protocol chart for the LATIN STEMI telecardiology program.

The protocol chart for the LATIN STEMI telecardiology program.


May 15, 2020 – A groundbreaking trial recently examined the viability of telemedicine for remote guidance of a population-based ST-segment elevation myocardial infarction (STEMI) program reaching more than 100 million patients. The study, presented as late-breaking science during the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Virtual Conference

The study helps further prove that telecardiology transcends boundaries, enabling millions of patients to have STEMI care access.

Telemedicine allows healthcare professionals to evaluate, diagnose and treat patients at a distance using telecommunications technology. Within the last decade, the approach has seen striking evolution and in the current COVID-19 climate, has become increasingly important to ensure patients have access to the care they need.

During the study, patients were triaged at spokes that included small clinics and primary healthcare centers in remote locations and transferred to hubs with percutaneous coronary intervention (PCI)-capability. The Latin America Telemedicine Network (LATIN) functioned between 2013 to present in four countries – Brazil, Colombia, Mexico and Argentina.

"As Americans see the benefits of telemedicine in the COVID-19 era, the findings of the [LATIN investigation] should be more relevant and noteworthy,” said Sameer Mehta, M.D., lead author and chairman of the Lumen Foundation. “LATIN is the result of dedicated efforts of more than 2,000 healthcare professionals, including about 600 physicians that were involved in this decade old program.”

Almost 900,000 patients presenting at 351 remote locations were triaged through a STEMI network. The program provided an umbrella of AMI protection to more than 100 million patients in Brazil, Colombia, Mexico, and Argentina. Mortality was reduced by 55 percent and the program contributed to saving $291 million. The results from LATIN trial surpass the total accumulated global experience with telemedicine.

The study investigators tested and proved four attributes of telemedicine:
   • Increased access • Increased accuracy.
   • Cost-effectiveness. 
   • Comprehensive, population-based care and delivery of guidelines-based acute myocardial infarction (AMI) management.

The program was created as a hub and spoke model that was used to expand access. Patients presented at remote clinics and primary care centers and were guided through telemedicine to receive thrombolysis, pharmaco-invasive management, or primary PCI. The role of the telemedicine experts was two-fold: urgent and accurate STEMI diagnosis and tele consultation of the entire STEMI process. Time to telemedicine diagnosis (TTD) was 3.5 minutes and it was possible from tremendous investment in IT infrastructure, with use of cloud computing, business intelligence tools and with GPS navigation. LATIN established TTD as a novel metric of telemedicine efficiency.

“LATIN has established the role of telemedicine in cost-effective and population-based management of AMI that reduces disparities of AMI care between developed and developing countries,” said Mehta. “It has provided a template that can be most beneficial for poorer regions on the world, including in sub-Saharan Africa, the Middle East and in southeast Asia. LATIN can also serve as a model of providing population-based coverage for other systems guided entities such as stroke."

Find links to the rest of the SCAI late-breaking trials and other SCAI news

 


Related Content

News | Cardiovascular Clinical Studies

October 14, 2022 — Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid ...

Home October 14, 2022
Home
News | Cardiovascular Clinical Studies

October 11, 2022 — The preliminary results of the first-in-human (FIH) trials for the innovative ELANA Heart Bypass ...

Home October 11, 2022
Home
News | Cardiovascular Clinical Studies

October 4, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase ...

Home October 04, 2022
Home
News | Cardiovascular Clinical Studies

September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term ...

Home September 08, 2022
Home
News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
Subscribe Now